Walgreens Boots Alliance Reports Mixed Q3 2025 Results Amid Pharmacy Growth
Walgreens Boots Alliance delivered a fiscal third-quarter performance marked by revenue growth but earnings disappointment. Sales climbed 7.2% year-over-year to $39.0 billion, exceeding analyst expectations, while adjusted EPS fell to $0.38 from $0.63 in the prior-year period.
The U.S. Retail Pharmacy segment drove top-line results with 7.8% sales growth to $30.7 billion, fueled by a 14.6% surge in comparable pharmacy sales. Management attributed the earnings shortfall to tax rate impacts, lower retail sales, and reduced equity earnings from pharmaceutical distributor Cencora.